Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

Abstract

BRAF plus MEK inhibitor combinations are currently FDA-positive nonmelanoma malignancies who received BRAF inhibitor approved for melanoma, non–small cell lung cancer, and anaplastic therapy, and data from published adult and pediatric trials. BRAF thyroid cancer. The lack of clinical benefit with BRAF inhibition in V600 mutations are prevalent across multiple nonmelanoma maligBRAF V600–mutated colorectal cancer has prevented its tissuenancies (>40 different tumor types), lead to oncogene addiction, and agnostic drug development. We reviewed the AACR GENIE data-are clinically actionable in a broad range of adult and pediatric base for the prevalence of BRAF V600 mutations across tumor nonmelanoma rare malignancies. Continued tissue-agnostic drug types. We reviewed the literature for case reports of clinical development is warranted beyond the current BRAF plus MEK responses, outcomes in patients with BRAF V600 mutation—approved cancers.